Literature DB >> 16183428

De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications.

Krista L Lentine1, Mark A Schnitzler, Kevin C Abbott, Leiming Li, Thomas E Burroughs, William Irish, Daniel C Brennan.   

Abstract

BACKGROUND: We aim to describe the risk, predictors, and outcomes associated with de novo congestive heart failure (CHF) after kidney transplantation.
METHODS: We used registry data from the US Renal Data System to retrospectively investigate de novo CHF in adult Medicare-insured transplant recipients and wait-listed candidates in 1995 to 2001. Heart failure was ascertained from inpatient and outpatient billing records, and participants were followed up until loss of Medicare or December 31, 2001. We used extended Cox hazards analysis to identify independent correlates of posttransplantation de novo CHF (adjusted hazard ratio [AHR], 95% confidence interval [CI]) and examine de novo CHF as a predictor of death and graft loss after transplantation.
RESULTS: In 27,011 transplant recipients, cumulative incidences of de novo CHF were 10.2% (95% CI, 9.8 to 10.6) and 18.3% (95% CI, 17.8 to 18.9) at 12 and 36 months and decreased to less than the demographic-adjusted incidence on the waiting list beyond the early posttransplantation period. Risk factors for de novo CHF included older recipient age, female sex, unemployed status at transplantation, pretransplantation comorbidities (anemia, diabetes mellitus, myocardial infarction, angina, cardiac arrhythmia, and peripheral vascular disease), transplant from older donors, donor cardiovascular death, and delayed graft function. We identified pretransplantation obesity, smoking, and posttransplantation complications, including hypertension, anemia, new-onset diabetes, myocardial infarction, and graft failure, as potentially modifiable correlates of de novo CHF. In separate analyses, de novo CHF predicted death (AHR, 2.6; 95% CI, 2.4 to 2.9) and death-censored graft failure (AHR, 2.7; 95% CI, 2.4 to 3.0).
CONCLUSION: Although associations may not reflect causality, identification of potentially mutable de novo CHF risk factors suggests targets for improving outcomes that should be evaluated prospectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183428     DOI: 10.1053/j.ajkd.2005.06.019

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  29 in total

1.  Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review.

Authors:  Krista L Lentine; Lisa A Rocca-Rey; Giuliana Bacchi; Nadia Wasi; Leslie Schmitz; Paolo R Salvalaggio; Kevin C Abbott; Mark A Schnitzler; Luca Neri; Daniel C Brennan
Journal:  Transplantation       Date:  2008-07-27       Impact factor: 4.939

2.  Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients.

Authors:  Krista L Lentine; Mark A Schnitzler; Kevin C Abbott; Kosha Bramesfeld; Paula M Buchanan; Daniel C Brennan
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

3.  Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.

Authors:  Jing Zhou; Lingfeng Qin; Tai Yi; Rahmat Ali; Qingle Li; Yang Jiao; Guangxin Li; Zuzana Tobiasova; Yan Huang; Jiasheng Zhang; James J Yun; Mehran M Sadeghi; Frank J Giordano; Jordan S Pober; George Tellides
Journal:  Circ Res       Date:  2015-09-23       Impact factor: 17.367

Review 4.  Primary care of the renal transplant patient.

Authors:  Gaurav Gupta; Mark L Unruh; Thomas D Nolin; Peggy B Hasley
Journal:  J Gen Intern Med       Date:  2010-04-27       Impact factor: 5.128

5.  The impact of kidney transplantation on heart failure risk varies with candidate body mass index.

Authors:  Krista L Lentine; Huiling Xiao; Daniel C Brennan; Mark A Schnitzler; Todd C Villines; Kevin C Abbott; David Axelrod; Jon J Snyder; Paul J Hauptman
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

6.  Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.

Authors:  Krista L Lentine; Lisa A Rocca Rey; Swathy Kolli; Giuliana Bacchi; Mark A Schnitzler; Kevin C Abbott; Huiling Xiao; Daniel C Brennan
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

7.  Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.

Authors:  Vikas R Dharnidharka; Mark A Schnitzler; Jiajing Chen; Daniel C Brennan; David Axelrod; Dorry L Segev; Kenneth B Schechtman; Jie Zheng; Krista L Lentine
Journal:  Transpl Int       Date:  2016-09-28       Impact factor: 3.782

Review 8.  Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies.

Authors:  Krista L Lentine; Frank P Hurst; Rahul M Jindal; Todd C Villines; Jeffrey S Kunz; Christina M Yuan; Paul J Hauptman; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2009-09-23       Impact factor: 8.860

Review 9.  Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Authors:  Roberto Marcén
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

10.  Urinary sulfur metabolites associate with a favorable cardiovascular risk profile and survival benefit in renal transplant recipients.

Authors:  Else van den Berg; Andreas Pasch; Welmoet H Westendorp; Gerjan Navis; Elizabeth J Brink; Reinold O B Gans; Harry van Goor; Stephan J L Bakker
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.